Skip to main content
Fig. 2 | The Journal of Headache and Pain

Fig. 2

From: Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials

Fig. 2

Major adverse events included in the study report. URTI: upper respiratory tract infection; UTI: urinary tract infection; A: lasmiditan 50 mg; B: lasmiditan 100 mg; C: lasmiditan 200 mg; D: rimegepant 75 mg; E: ubrogepant 25 mg; F: ubrogepant 50 mg; G: ubrogepant 100 mg; H: zavegepant 5 mg; I: zavegepant 10 mg; J: zavegepant 20 mg; K: placebo

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us